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The genetic channelopathies are a broad collection of diseases. Many ion channel genes 
demonstrate wide phenotypic pleiotropy, but nonetheless concerted efforts have been made to 
characterise genotype-phenotype relationships. In this review we give an overview of the factors 
that influence genotype-phenotype relationships across this group of diseases as a whole, using 
specific individual channelopathies as examples. We suggest reasons for the limitations observed in 
these relationships. We discuss the role of ion channel variation in polygenic disease and highlight 
research that has contributed to unravelling the complex aetiological nature of these conditions. We 
focus specifically on the quest for modifying genes in inherited channelopathies, using the voltage-
gated sodium channels as an example. Epilepsy related to genetic channelopathy is one area in 
which precision medicine is showing promise. We will discuss the successes and limitations of 
precision medicine in these conditions. 
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Highlights 
• The genetic channelopathies are a broad group of diseases which affect multiple organ 
systems 
• Most genetic channelopathies demonstrate marked phenotypic pleiotropy 
• Mechanisms that underpin phenotypic pleiotropy include functional effects of specific 
mutations, the effects of modifying genes, and environmental influences 
• Precision medicine treatment of channelopathies has shown early promise, but faces a 














Ion channels are a broad category of transmembrane proteins that share the physiological property 
of being involved in the regulation of ion flux across cell membranes. In the human genome there 
are over 400 genes encoding ion channels. Ion channels are expressed in almost all cell membranes, 
as well as in the membranes of many intracellular organelles, and they are involved in a diverse 
range of physiological processes. It is therefore no surprise that ion channel dysfunction has been 
implicated in a wide spectrum of human diseases. The clinical features and age of presentation of 
diseases related to ion channel dysfunction are dependent on the physiological role of the ion 
channel in question, as well as the tissue-specific and age-specific expression of its gene(s). Many 
different mechanisms may lead to ion channel dysfunction, including primary genetic defects in the 
coding sequence for the channel protein itself, genetic defects in genes and/or noncoding DNA 
implicated in the expression and regulation of ion channel genes, and acquired ion channel 
dysfunction as a result of autoimmune destruction of ion channels, which itself is likely to have 
genetic determinants. Acquired ion channel dysfunction has been observed in rats with chemically-
induced seizures, and is likely to involve a mixture of direct toxic/ischaemic damage to ion channels, 
epigenetic dysregulation of ion channel genes, and intrinsic susceptibility to ion channel dysfunction. 
In turn, intrinsic susceptibility to ion channel dysfunction is likely to be determined by genetic 
variants in the ion channel itself, variants in genes that are involved in regulating ion channel genes, 
and the immune system. Thus, in the channelopathies, as with most human disease, a picture 
emerges of a complex interplay between genetic, epigenetic, and environmental factors. The case 
that such complex interplay is likely to underlie all the channelopathies, even those with apparently 
“monogenetic” causes, is evidenced by the finding that clear genotype-phenotype relationships are 














Since ion channels are present in almost all tissues, and they perform a wide range of functions, ion 
channel disease presents a highly diverse group of conditions. Figure 1 summarises the currently 















A brief glance at Figure 1 will immediately reveal that pathogenic variants in many ion channel genes 
are associated with remarkable phenotypic pleiotropy.  For example, heterozygous mutations in the 
potassium channel gene KCNQ2 have been identified in three distinct neurological disorders: self-
limiting familial neonatal seizures(Singh et al. 1998), early infantile developmental and epileptic 
encephalopathy(Weckhuysen et al. 2012),  and peripheral nerve hyperexcitability(Wuttke et al. 
2007). In some cases phenotypic pleiotropy extends beyond a single organ system: KCNJ5 mutations 
have been found in long-QT syndrome(Yang et al. 2010), Andersen Tawil Syndrome (a multisystem 
disorder characterized by periodic paralysis, ventricular arrhythmias, and distinctive dysmorphic 
facial and/or skeletal features)(Kokunai et al. 2014), and in familial hyperaldosteronism(Choi et al. 
2011). In fact, phenotypic pleiotropy is more the rule than the exception in the genetic 
channelopathies. Now that the extent of phenotype variability associated with ion-channel genes 
has been widely appreciated, recent scientific efforts have focussed gaining a deeper understanding 
of how any particular mutation may relate to the phenotype seen: the so-called “genotype-
phenotype relationship.” 
Factors influencing the genotype-phenotype relationship 
1. Mutation hotspots 
In all known ion channel diseases in which non-truncating variants have been implicated, mutational 
hotspots, regions of the gene where there is clustering of pathogenic variants in association with 
disease, are seen. These hotspots correspond with functionally important regions of the ion channel, 
such as the voltage-sensor region, ligand binding site, or the pore-forming region(Zuberi et al. 2011). 
These regions demonstrate low mutational tolerance across species and within healthy human 













is observed, there is a sense that in more severe cases, mutations are more likely to be observed in 
functionally important regions, though even in one of the most well studied channelopathy genes, 
SCN1A, this remains to be proven(Harkin et al. 2007). 
2. Single variant correlations 
In a minority of channelopathies certain phenotypes have only ever been observed in association 
with a single variant, or amino acid change. An example of this is CAPOS (Cerebellar ataxia, Areflexia, 
Pes cavus, Optic atrophy, and Sensorineural deafness) syndrome, which is caused by heterozygous 
mutations in the ATP1A3 gene, encoding the catalytic α3 subunit of the Na
+/K+ ATPase. Heterozygous 
missense mutations in ATP1A3 have been observed in two other phenotypes: alternating hemiplegia 
of childhood (AHC) (Rosewich et al. 2012), and rapid onset parkinsonism dystonia (RPD)(de Carvalho 
et al. 2004). In AHC and RPD, causative mutations have been identified across the length of the gene, 
though only one variant (p. Asp923Asn) has been found in both AHC and RPD patients(Zanotti-
Fregonara et al. 2008, Anselm et al. 2009, Roubergue et al. 2013). However, in CAPOS syndrome, 
only a single, recurrent, causative variant (p.Glu818Lys) has been identified(Demos et al. 2014, 
Heimer et al. 2015, Potic, Nmezi & Padiath 2015). It has been postulated that the reason that the 
p.Glu818Lys mutation leads to a the distinct phenotype of CAPOS syndrome is because this mutation 
would be predicted to lead to a gain-of-function in the ion channel(Demos et al. 2014), whereas the 
disease-causing mutations seen in AHC and RPD cause a loss-of-function)(de Carvalho et al. 2004). 
However, no formal functional studies have been published using a p.Glu818Lys model to back up 
this theory. With mutations in the potassium channel gene KCNQ2, the phenotype seen is of focal 
tonic seizures beginning in the first days of life. Recently, the single variant (p.Arg198Glyn) has been 
found in five cases who did not have neonatal seizures, but presented with infantile spasms, 
hypsarrhythmic EEG, and marked developmental regression between 4 and 6 months of life. Using in 
vitro electrophysiology studies, the authors demonstrated that this variant conferred gain-of-













are associated with a wide variety of epilepsy phenotypes, the recurrent p.Arg853Gln variant has 
been found exclusively in cases presenting with infantile spasms(Wolff et al. 2017, Brain). 
3. Predicted pathogenicity of variants 
A number of commercially available in silico tools (SIFT®, Polyphen®, Mutation Taster®) are 
frequently used to help geneticists predict the likely pathogenicity of genetic variant that has been 
identified through sequencing. These tools typically incorporate information about the evolutional 
conservation of the affected sequence as well as observed mutation rates in healthy populations. 
Often, in clinical practice, such tools are used in a rather binary fashion to determine whether a 
genetic variant is causative or not. However, in reality there is likely to be a spectrum of 
pathogenicity observed with many rare variants. In time, if large shared datasets are collected 
systematically, in silico tools may be used to help define the spectrum of many channelopathies. 
The best example of a channelopathy in which the pathogenicity scores have been shown to 
correlate with phenotype is epilepsy due to SCN1A mutations.  To date more than 1200 different 
mutations in the SCN1A gene have been identified in association with epilepsy(Djémié et al. 2016). 
Milder cases of SCN1A-related epilepsy are often inherited and cause familial febrile seizures, and 
genetic epilepsy with febrile seizures plus (GEFS+)(Claes et al. 2001), whereas at the opposite end of 
the phenotypic spectrum is Dravet syndrome, a severe epilepsy beginning in infancy, in which 
developmental stagnation is often seen with epilepsy onset(Escayg et al. 2000). Zuberi et al. 
demonstrated that where SCN1A mutations affected the voltage sensing region of the channel, 
patients with Dravet syndrome had significantly greater silico  evidence of pathogenicity than 
patients with GEFS+ (Zuberi et al. 2011). 
4. Functional effects of mutations 
Defining the functional effects of a genetic variant is gold standard for proving pathogenicity, and 













lines (for example human embryonic kidney cells or Xenopus laevis oocytes) with the variant being 
investigated, and then using the patch clamp technique(Neher and Sakmann 1976) to measure the 
properties of ion currents compared with wild-type cells(Shalaby et al. 1997). 
Based on such functional characterisations, ion channel mutations are often referred to as either 
“loss-of -function” or “gain-of-function,” though in reality such terms oversimplify what are often 
complex alterations in ion channel function(Swanger et al. 2016). Broadly speaking, loss-of-function 
mutations are associated with reduced channel permeability, and gain-of-function mutations lead to 
an increase in ion flux. 
Loss-of-function: 
On the whole, disease causing missense mutations in ion channel genes are more likely to result in 
reduced permeability (loss-of-function) than increased permeability (gain-of-function). Reduced ion 
permeability may also result from a whole gene deletion or truncation mutation as a result of 
halpoinsufficiency. For some ion channels, such as Nav1.1 and Kv7.2(Schroeder et al. 1998) normal 
ion channel function appears to be dependant on biallelic expression of the gene, whilst other ion 
channels, such as CFTR, entirely tolerate haploinsufficiency without apparent functional 
consequence. Therefore, in the absence of functional studies, loss-of-ion channel function cannot be 
inferred from the finding of a nonsense mutation, frameshift mutation, or whole gene deletion (null 
mutation). Furthermore, even in ion channels that do not tolerate haploinsuffiency, the functional 
consequences of null mutations may differ from those of loss-of function missense mutations. 
Compared with null mutations, loss-of-function missense mutations may either result in a 
functionally less impacted channel, due to residual function of the mutant channel, or conversely in 
a more severely affected channel, where there is a dominant-negative impact from the mutant on 
the wildtype channel(Shalaby et al. 1997, Warner et al. 2016). A good example of how loss-of-
function can take several different forms, and how this can influence phenotype, is seen with 













in skeletal muscle. Gain-of-function mutations in CHRND cause slow channel congenital myaesthenic 
syndrome(Gomez et al. 2002), whilst loss-of-function of this channel can take three forms, with each 
associated with a different phenotype: recessive missense mutations that result in a slowing of 
channel opening cause fast channel congenital myasthenic syndrome(Gomez et al. 2002); recessive 
missense mutations that impair co-clustering of the acetylcholine receptor with rapsyn lead to 
reduced expression of normally functioning receptors, and have been found in association with a 
more severe congenital myasthenic syndrome(Müller et al. 2006); and recessive truncation 
mutations (i.e. complete deficiency) cause the most severe phenotype of multiple pterygium 
syndrome, an embryonically lethal syndrome associated with multiple bone and spinal 
fusions(Michalk et al. 2009). For some channelopathies distinct phenotypes are seen in the 
haploinssufficient state compared with the complete deficiency state (as a result of biallelic loss-of-
function mutations). With SCN4A, heterozygous loss-of-function mutations lead to hypokalaemic 
periodic paralysis, hyperkalamic periodic paralysis or paramyotonia congenita(Ptáček et al. 1991, 
Jurkat-Rott et al. 2000, Ptáček et al. 1992), whilst biallelic loss-of-function mutations are associated 
with a distinct phenotype of congenital myasthenic syndrome(Tsujino et al. 2003). 
Gain-of-function: 
Even more than loss-of-function mutations, gain-of-function changes are currently very difficult to 
impute or model in silico, and almost always require in vitro techniques such as patch clamp to 
demonstrate. “Gain-of-function” refers to a variety of possible functional changes. Channels may be 
rendered in a permanently open state, or there may be an increased frequency of channel opening, 
and increased sensitivity to ligand binding, or delayed channel closure. These different gain-of-
function effects demand different techniques to demonstrate. It has been shown in epilepsy related 
to gain-of-function KCNT1 and KCNQ2 variants, that the degree of increased channel permeability 
correlates with the severity of the phenotype(Millichap et al. 2017, Milligan et al. 2014). To infer 













which mutant channel subunits are expressed relevant in human brain tissue may not be known, and 
reduced cell surface expression of apparently functionally enhanced subunits, as a result of impaired 
trafficking(Swanger et. al 2016) may counteract any gain of function properties(Martin et al. 2010). 
Demonstration of a gain-of-function mutation can have important therapeutic implications, since it 
is currently easier to block ion channels with medications than to open dysfunctional ones. This will 
be discussed in the precision medicine section of this paper. 
Channelopathies with opposing phenotypes: 
There are some genetic channelopathies that demonstrate marked differences in the phenotypes 
observed with loss-of-function mutations versus gain-of-function mutations. The best examples of 
this are the congenital disorders of pain related to sodium channel mutations, and some of the 
potassium channel-related cardiac dysrhythmias.  
The sodium channel gene SCN9A encodes Nav1.7, which is expressed predominantly in dorsal root 
ganglion cells and sympathetic ganglion neurons(Toledo-Aral et al. 1997). Gain-of-function 
mutations in SCN9A have been found in two conditions characterised by excessive pain perception, 
primary erythromelagia and paroxysmal extreme pain disorder(Fischer and Waxman 2010) whilst 
biallelic loss-of-function mutations in the same gene have been found in what could be considered 
an opposing phenotype, congenital insensitivity to pain(Cox et al. 2006). A similar picture is seen in 
the cardiac channelopathies caused by KCNH2 and KCNQ1 where gain-of-function mutations are 
found in short QT syndrome(Brugada et al. 2004, Bellocq et al. 2004), whilst loss-of-function 
mutations are seen in long QT syndrome(Curran et al. 1995, Wang et al. 1996). These could also be 
considered opposing phenotypes, although both predispose to cardiac arrhythmias. 
Complex genotype-phenotype relationships: 
Stark contrasts between the phenotypes associated with gain-of-function and loss-of-function in ion 













and phenotype is observed. This is particularly the case with conditions that are known to have 
complex genetic aetiologies, such as epilepsy and the predisposition to cardiac dysrhythmia, where 
other genetic modifiers are likely to complicate the relationship between genotype and phenotype. 
These will be discussed in the section on the quest for modifying genes. Gain-of-function and loss-
of-function mutations of KCNA2 have both been associated with a severe early-onset epilepsy 
phenotype, though efforts have been made to delineate the two phenotypes, which may become 
clearer with the discovery of more cases(Syrbe et al. 2015). Similarly, both gain- and loss-of-function 
variants have been found in severe early onset epilepsies caused by KCNB1(Torkamani et al. 2014), 
KCNQ2(Weckhuysen et al. 2012, Millichap et al. 2017), GRIN2A(Carvill et al. 2013), GRIN2B(Lemke et 
al. 2014), HCN1(Nava et al. 2014), and SCN2A(Wolff et al. 2017), as well as in GEFS+ caused by 
SCN1A mutations(Lossin et al. 2002). These findings suggest that in a state of health neuronal 
networks expressing these ion channels are poised in a state of equilibrium, the disruption of which, 
in either direction, can lead to excessive synchronous excitation(Swanger et al. 2016). One of the 
reasons why disruption of this equilibrium in either direction can predispose to seizures is likely 
because most of these channels are expressed in both excitatory and inhibitory neurones. This is 
important to bear in mind when using drugs that act on ion channels to treat epilepsy since some 
drug classes when used in patients with particular channelopathies may lead to a paradoxical 
exacerbation of seizures, as is seen with the use of sodium-channel-blocking drugs in SCN1A-related 
epilepsies(Brunklaus et al. 2013, Ogiwara et al. 2007). 
In some channelopathy-related epilepsies, a clear genotype-phenotype relationship is seen at one 
end of the mutational spectrum, but the relationship becomes less clear beyond that. For example in 
SCN1A-related epilepsy a severe phenotype is typically seen with whole gene deletions and 
truncating mutations compared with missense mutations(Zuberi et al. 2011), whilst in KCNQ2-
related epilepsies the opposite is true, and whole gene deletions and truncation mutations are 
associated with self-limiting seizures(Singh et al. 1998, Biervert et al. 1998, Allen et al. 2014, Claes et 













with missense mutations, presumably due to gain-of-function, or dominant negative 
effects(Weckhuysen et al. 2012, Millichap et al. 2017, Miceli et al. 2013, Saitsu et al. 2012, Borgatti 
et al. 2004). 
Such is the complexity of genotype-phenotype relationships in the channelopathies, and the myriad 
of variables that could potentially influence this, progress in this area will undoubtedly depend on 
large international data-sharing efforts in which extensive phenotype and genotype data are shared 
in common databases, as exemplified by the Epilepsy Phenome/Genome project 
(http://www.epgp.org). 
Ion channel-regulating genes 
The genetic channelopathies are not restricted purely to conditions caused by mutations in genes 
encoding the ion channels themselves. Many other genes are likely to play roles in the regulation of 
ion channels at molecular (e.g. accessory subunits), transcriptional (e.g. chromatin regulating genes), 
and translational (e.g. microRNA)(Jiang, Zhang and Chan 2012, Wang 2013) levels. Genes encoding 
ion channel accessory subunits are included in red in the data supplement. Pathogenic mutations in 
CNTN2(Stogmann et al. 2013) and CNTNAP2(Strauss et al. 2006), which encode contactin associated 
protein 2 (CASPR2) have been shown to disrupt clustering of potassium channels at the nodes of 
Ranvier in myelinated axons(Poliak et al. 2003, Peñagarikano et al. 2012) and cause a childhood-
onset epilepsy with associated regression in speech development(Smogavec et al. 2016). FGF12 and 
FGF13 encode fibroblast growth factor proteins which interact with the C-terminus of voltage gated 
sodium channels(Goldfarb 2012), and mutations in these genes have been found in patients with 
similar phenotypes to those seen in SCN1A-related epilepsy(Puranam et al. 2015, Siekierska et al. 
2016, Al-Mehmadi et al. 2016). In cardiology, a large number of genes(Shy, Gillet and Abriel 2013), 
including SNTA1(Wu et al. 2008), MOG1(Kattygnarath et al. 2011), and GP1DL(Van Norstrand et al. 
2007) have been shown to interact with Nav1.5, and have been implicated in causing Brugada and 













a major role in the localisation of skeletal muscle acetylcholine receptors(Apel et al. 1995), and 
RAPSN mutations are associated with congenital myaesthenic syndrome (Ohno et al. 2002) and fatal 
akinesia deformation sequence (Michalk et al. 2009). 
The role of ion channels in complex genetic diseases 
The role of ion channel mutations in disease extends beyond rare monogenic diseases. 
Polymorphisms in ion channel genes have been implicated in susceptibility to several common 
diseases, including schizophrenia(Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) 
Consortium 2011), common forms of epilepsy(International League Against Epilepsy Consortium on 
Complex Epilepsies 2014), atrial fibrillation(Ellinor et al. 2012), and diabetes(Reis et al. 2000, Hansen 
et al. 2005). Genome wide association studies (GWAS) are powered to identify relatively common 
variants (typically found in ≥5% of the population) that have a moderate impact on disease 
susceptibility across the population as a whole. Very large sample sizes are needed to detect variants 
with genome-wide significance, and many relevant genetic contributes to common disease are likely 
to be missed by current GWAS approaches thanks to said variants being too rare, or too small in 
effect size. Furthermore, variant signals picked up by GWAS may not necessarily be causative per se 
since all inherited variants in a population segregate to some extent with other variants in nearby 
genes, a phenomenon known as linkage disequilibrium. Nonetheless it is worthy of note that 
genome wide significance has been reached for an SCN1A variant in a meta-analysis of epilepsy 
GWAS (total 8,696 cases and 26,157 controls)(International League Against Epilepsy Consortium on 
Complex Epilepsies 2014), for CACNA1C in a schizophrenia GWAS (8,422 cases and 21,397 controls)( 
Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium 2011), and for both 
KCNN3 and HCN4 in atrial fibrillation(6,707 cases and 52,426 controls)(Ellinor et al. 2012).  
An alternative approach to GWAS that can be used to identify rarer variants that may play a role in 
common disease susceptibility is to compare the number of observed rare variants in any given gene 













analysis. Ion channels that have been implicated in type 2 diabetes through this type of methodology 
have been KCNJ11(Hansen et al. 2005) and ABCC8(Reis et al. 2000). With regards to epilepsy, the 
Epi4K consortium and Epilepsy Phenome/Genome project expanded this methodology to compare 
the exomes of 1185 individuals with familial epilepsies with 3,877 control subjects. In the epilepsy 
group there were significantly higher proportions of ultrarare variants in a number of ion channel 
genes, including GABRG2, SCN1A, ATP1A3, KCNQ2, CACNA1B, and GRIN2A(Epi4K consortium, 
Epilepsy Phenome/Genome Project 2017). The authors concluded “that genes established as 
responsible for familial and rare severe epilepsies are also associated with common epilepsies.” 
Atrial fibrillation and epilepsy are examples of common diseases that appear to have both single 
gene causes and polygenic causes, and yet the very same genes have been implicated in both types 
of causation. Because these are such commonly observed phenotypes, disentangling the relative 
contribution of any given gene remains an enormous challenge, if not an impossibility. The genetic 
aetiology of these conditions is therefore perhaps best conceptualised as part of a spectrum, as 
illustrated in Figure 2. 
The quest for modifying genes 
In all but the most severe and highly penetrant single gene channelopathies, genetic modifiers are 
presumed to exist, since phenotypic variability is observed among those harbouring identical genetic 
mutations. For example, in affected members of families with genetic epilepsy with febrile seizures 
plus (GEFS+) due to mutations in SCN1A, there are some individuals with a markedly more severe 
phenotype(Escayg et al. 2000). The same phenomenon is observed in GEFS+ families with GABRG2 
mutations(Harkin et al. 2002), and in families with KCNQ2 mutations, the majority of whom have 
self-limiting neonatal seizures, but some of whom continue to have epileptic seizures into childhood 
and adulthood(Singh et al. 2003). Whilst SCN1A truncations are generally found in association with 
more severe phenotypes, and in patients who experience a seizure-worsening when the anti-













truncations who have mild phenotypes and Carbamazepine-responsiveness(Takaori et al. 2017). In 
some channelopathies entirely different phenotypes can be seen in association with an identical 
mutation. For example in a family in which the mother and son shared the same missense mutation 
in ABCC8 the son presented with congenital hyperinsulinism, whilst the mother had a focal epilepsy 
but demonstrated completely normal regulation of insulin secretion(Stranks et al. 2016). The 
concept of genetic modifiers is most compelling in the monogenic forms of epilepsy, autism, and 
cardiac arrhythmias – conditions where complex polygenic aetiology is already presumed to exist for 
the majority of cases, and the role of common, low-effect variants is already established(Speed et al. 
2014). However, the challenge of identifying genetic modifiers is huge. GWAS requires large sample 
numbers to identify genomic signals of disease association, so to apply this same methodology to 
approach the identification of genetic modifiers in a small number of cases where a rare monogenic 
cause has been identified is an impossibility. 
Mouse models of sodium channel related epilepsy have however made some headway in identifying 
candidate disease modifying genes thanks to the initially serendipitous discovery that SCN2A 
mutants demonstrate a strain-dependant phenotype. Hawkins et al. found that in the SCN2AQ54 
(mice carrying the gain-of-function mutation GAL879-881QQQ) model of epilepsy [B6XSJL/J]F1 mice 
demonstrated a more severe phenotype than C57BL/6J mice. They used mapping techniques to 
identify a possible modifying variant on the HLF (hepatic leukaemia factor) gene. They then crossed 
both SCN2AQ54 and SCN1A knockout mice with HLF knockout mice and demonstrated that in both 
SCN1A and SCN2A models HLF deficiency was associated with a more severe phenotype. Because 
HLF haploinsufficiency is believed to result in downregulation of the pyridoxal kinase enzyme which 
converts pyridoxine to pyridoxal 5’ phosphate, they gave the SCN2AQ54 mice a pyridoxine restricted 
diet and demonstrated a worsening of seizures(Hawkins and Kearney 2016). Further work by this 
same group on mouse models has identified candidate genetic modifiers of sodium channel epilepsy 













partially rescued by Clobazam(Hawkins et al. 2016), and a CACNA1G variant in the SCN2AQ54 mutant 
model(Calhoun et al. 2016). 
In a parallel story, mouse models have been used to investigate for genetic modifiers of cardiac 
channelopathies. Remme et al. demonstrated that in an SCN5A1798insD/+ model, 129P2 mice 
demonstrated a more severe phenotype than FVB/N mice. They used pan-genomic mRNA 
expression techniques to uncover a dramatic reduction in SCN4B mRNA in the more severely 
affected strain(Remme et al. 2009). 
In humans, evidence for genetic modifiers of channelopathies is largely limited to isolated case 
reports of patients with pathogenic or possible pathogenic mutations identified in additional genes 
to the primary ion channel – often referred to as “blended phenotypes.” Examples of such blended 
phenotypes include: a family with SCN5A-related cardiac conduction disorder in which the presence 
of a p.Lys897Thr variant in HERG2 segregated with those members of the family who had a more 
severe phenotype (Jagodzinska et al. 2016); an individual with a very severe progressive cardiac 
conduction disorder who was found to have predicated damaging mutations in both KCNK17 and 
SCN5A(Friedrich et al. 2014); and 2 siblings who had basal ganglia calcifications and generalized 
epilepsy who were found to have heterozygous damaging mutations in both CHRNB2 (known to be 
associated with familial epilepsy) and SLC20A2 (known to cause primary familial basal ganglia 
calcification)(Fjaer et al. 2015). There is also increasing evidence that common polymorphisms 
elsewhere in the same ion channel gene that is believed to be causative of the disease may influence 
phenotype. This phenomenon has been reported for the c.1059G>A polymorphism in KCNQ1 which 
has been associated with further prolongation of the QT interval in patients with long QT syndrome 
due to pathogenic KCNQ1 mutations(Kapplinger et al. 2017), and with the SCN4A p.Ser906Thr 
polymorphism which appears to exacerbate the phenotype of patients with hyperkalaemic periodic 













It is of course equally possible that some genetic variants confer relative protection from 
channelopathy-related disease, but these are likely to be even harder to identify than deleterious 
genetic modifiers. In a mouse model of SCN1A-related Dravet syndrome, knockout of both Tau 
alleles resulted in a milder phenotype with reduced epileptic spikes on EEG, and improved learning, 
memory and executive function(Gheyara et al. 2014). Similarly, knockout of SCN2A has been 
demonstrated to improve survival in a KCNA1-null mouse model of SUDEP (Mishra et a. 2017). 
Precision medicine 
The ion channel-related epilepsies are an area of medicine where precision therapy has shown early 
promise. The idea that dysfunctional channels can be targeted with drugs acting on them is a highly 
attractive one, particularly as this has emerged as a possibility in an area of medicine where 
treatment resistance is common(Berg et al. 2009, Cockerell, Sander and Shorvon 1995), and 
evidence based therapy is lacking(Marson et al. 2007a, Marson et al. 2007b). Intuitively it is easier to 
use drugs to block the action of an overactive ion channel than to open up an underactive one, and 
this has proven to be the case, with the majority of precision medicine successes reported so far 
being in cases where there is a gain-of-function channelopathy. Due to the extreme rarity of these 
cases, all evidence base is restricted to anecdotes. Nonetheless these at least provide a proof-of-
principle for precision medicine in channelopathies. 
Current approaches to precision-medicine begin with identification of the genetic cause of a disease 
and thereafter take two broad forms: i) rational choice of existing therapies based on established 
evidence or known mechanisms of action; ii) systematic screening for novel or repurposed drugs 
using models that incorporate the mutation or genetic mechanism. In future is it possible that 
precision medicine may not need, nor indeed benefit, from exact knowledge of genetic causation. If 
high throughput induced progenitor stem cell (iPSC) models can be developed for drug screening, 
then it may be possible to identify the optimum medication for an individual’s disease based on a 













modifying genes(Avior, Sagi and Benvenisty 2016), though such models would fail to account for the 
tissue-specific effects of somatic mutations. Another future avenue for precision medicine is the 
development of non-genomic biomarkers that predict treatment response, such as metabolomic 
profiles, or functional and spectroscopic imaging(Al Zweiri et al. 2010).  
Rational therapy choice based on established evidence/known mechanisms of action 
This type of precision medicine is already common practice in some childhood-onset epilepsies. 
When a patient is found to have an SCN1A mutation, most clinicians will withdraw, or avoid using, 
any sodium channel blocking medications, based on anecdotal reports of seizure-
worsening(Brunklaus et al. 2013). This approach can be rationalised by the knowledge that these 
mutations cause loss-of-function and that Nav1.1 is preferentially expressed in inhibitory 
interneurons(Ogiwara et al. 2007). Therefore further reducing the excitability of these inhibitory 
neurones  through sodium channel blockade would be expected to promote overall neuronal 
excitability. Loss-of-function mutations in KCNQ2 can cause self-limiting familial neonatal seizures as 
well as a more severe phenotype of early-onset developmental and epileptic encephalopathy. In 
KCNQ2 anecdotal evidence supports the use of sodium channel blocking drugs(Pisano et al. 2015). 
This can be rationalised on the basis that most KCNQ2 mutations are loss-of-function, and that Kv7.2 
is preferentially expressed in excitatory hippocampal neurones. Loss of Kv7.2 function results in an 
increased intracellular K+ concentration. If the resulting reduction in polarisation of the neuronal cell 
membrane is counteracted by blocking the inwards movement of sodium ions, the increased 
excitability may be balanced out. Other examples of how the scientific understanding of the action 
of an ion channel has helped to guide drug choice are the use of Mexilitine in SCN2A-related 
epilepsy(Foster et al. 2016), Retigabine (a potassium channel opener) for KCNQ2/KCNQ3-related 
epilepsies (Millichap et al. 2016), and sulphonylureas in neurodevelopmental disorders related to 













In long QT syndrome, beta blockers are thought to be the most rational treatment choice for 
patients with KCNQ1 mutations(Barsheshet et al. 2012), whilst medications that preferentially act on 
the fast inactivation type of sodium channel, are believed to be most effective for those with SCN5A-
(Moss et al. 2008, Priori et al. 2000). 
Using in vitro and in vivo models to screen for effective drugs 
This can be done on a small scale using individual patient genotypes to test a limited number of 
rationally chosen drugs, or on large scale using high throughput models of genetic channelopathy to 
test a large number of drugs. The main reported successes of the former approach are with 
epilepsies due to gain-of-function mutations in KCNT1, GRIN2A, GRIN2D, and SCN8A. 
Following anecdotal reports of treatment success of quinidine in KCNT1-related severe epilepsies 
(Bearden et al. 2014), Mikati et al. demonstrated in vitro that quinidine inhibited hKCNT1 currents in 
a Xenopus oocyte model. The oocytes expressed the mutations found in two patients with epilepsy 
of infancy with migrating focal seizures (EIMFS) due to de novo KCNT1 mutations. Both patients were 
subsequently treated with quinidine, but only one had a clinically detectable reduction in 
seizures(Mikati et al. 2015). The reason for these discordant clinical responses to quinidine despite 
similar in vitro evidence for efficacy is unclear, and highlights the need to consider the functional 
impact of mutations within a more systems-wide context. 
Almost identical approaches, involving in vitro testing of drugs in Xenopus oocytes or human dorsal 
root ganglion cells expressing the mutations found in real patients, prior to a trial of medication, 
have been used successfully in GRIN2A (Memantine)(Pierson et al. 2014), GRIN2D (Memantine and 
Magnesium sulphate)(Li D. et al. 2016), SCN8A (Phenytoin)(Barker et al. 2016), SCN4A(Desaphy et al. 
2016), and  SCN9A(Carbamazepine)(Geha et al. 2016). 
Whilst these small scale and highly personalised approaches have clearly delivered results to the 
patients concerned, scaling them up remains a challenge, and the number of drugs that has been 













medications for efficacy in specific genetic channeloapthies using iPSC(Avior, Sagi and Benvenisty 
2016) and in vivo whole organism models has facilitated the identification of new and repurposed 
medications. For example, through in vivo modelling in zebrafish identified Clemizole (an 
antihistamine) as a potential treatment for SCN1A-related epilepsy(Baraban, Dinday and Hortopan 
2013). Whilst whole organism models have the advantage of more accurately reflecting complete 
neuronal circuitry, they are more expensive to produce, and are not specific for an individual genetic 
variant. 
SCN1A as an example of the challenges facing precision medicine 
Whilst in Dravet syndrome knowledge of the SCN1A mutation does appear to provide clinicians with 
immediately tangible information to guide treatment choice,(Brunklaus et al. 2013), in reality the 
relationship between genotype and treatment response is likely to be highly complex. There are 
reports of patients who in fact benefit from sodium channel blocking medications, and who 
experience a deterioration when these medications are withdrawn(Takaori et al. 2017, Dalic  et al. 
2015). To some extent, variations in medication response may be explained by the location and 
functional effect of the SCN1A mutation. There is some suggestion that those patients with SCN1A 
truncation mutations are more likely to respond to Stiripentol and Topiramate, whilst those with 
missense mutations are more likely to respond to Clonazepam and Triple Bromide. However these 
data come from retrospective reports from clinicians and must be viewed with caution(Ishii et al. 
2016). As discussed above, dividing mutations into truncating and non-truncating oversimplifies the 
functional consequences of genetic variants. To truly understand medication response in SCN1A-
related epilepsy a more complete analysis of the functional effects of specific missense mutations is 
required, as well as a consideration of the influence of Nav1.1 channel expression and distribution 














Many other genetic factors are likely to have an impact on treatment response, besides the 
particularities of the ion channel mutation. These include: predisposition to specific adverse drug 
reactions, which is often related to HLA type(Amstutz et al. 2014); genetic variants that affect drug 
absorption, distribution, metabolism, and elimination(Chen et al. 2014, Shaheen et al. 2014, Löscher 
et al. 2009, Saygi et al. 2014); and genetic variation at the site of drug targets, which in the case of 
channelopathy treatment, are often in fact ion channels themselves(Thompson, Kahlig and George 
2011). It is important to bear all of these in mind where precision medicine is an objective. 
5. Conclusion 
We have now entered a very exciting era of genomic medicine, in which obtaining whole genome 
information on individuals is rapidly becoming the most cost effective way to diagnose rare genetic 
disease. As the use of Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS) 
becomes more widespread it is almost certain that new ion channel genes will be linked to both 
monogenic and complex genetic diseases, and that new genotype-phenotype relationships will 
emerge. Large scale analysis of whole genome data will also provide the opportunity to identify 
relevant genetic modifiers in “monogenic” channelopathies, some of which may have significant 
implications for treatment. The emergence of such genetic modifiers will lead to a fundamental 
reconceptualization of monogenic and complex genetic diseases as existing on a continuous 
spectrum. The genetic channelopathies are an area where precision medicine has shown early 
promise, though as yet no model that accurately expresses both genetic modifiers and systems wide 
context has been developed. To permit widespread application of precision techniques current 
technical and financial barriers will need to be overcome. 
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Figure 1 – Summary of the known human genetic channelopathies 
Figure 2 - schematic of how SCN1A mutations fit into all models of epilepsy inheritance 
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PRESENTING WITH SEVERE EARLY-ONSET EPILEPSY 
SODIUM CHANNELS 




LOF α subunit of the type 1 neuronal voltage-gated sodium 
channel (Nav1.1) 
Voltage Sodium SCN1A (Escayg et al. 2000) 
 
(B) EOEE Recessive 
 
LOF β1 auxiliary subunit for the type 1 neuronal voltage-gated 
sodium channel 
Voltage Sodium SCN1B (Patino et al. 2009) 
 
(C) Early infantile epileptic encephalopathy 
EIMFS 








α subunit of the type 2 neuronal voltage-gated sodium 
channel (Nav1.2) 
Voltage Sodium SCN2A (Ogiwara et al. 2009) 
(Dhamija et al. 2013) 
(Tavassoli et al. 2014) 
(D) EOEE Dominant  GOF α subunit of the type 6 neuronal voltage-gated sodium 
channel (Nav1.6) 
Voltage Sodium SCN8A (Veeramah et al. 2012) 
 
(E) Epileptic encephalopathy with 
neuromuscular disease 
Recessive LOF α subunit of the type 8 neuronal voltage-gated sodium 
channel (Nav1.8) 
Voltage Sodium SCN10A (Kambouris et al. 2016) 
POTASSIUM CHANNELS 
(F) EOEE Dominant LOF and GOF α2 subunit of Shaker family potassium channels (Kv1.2) Voltage Potassium KCNA2 (Syrbe et al. 2015) 
 EOEE Dominant LOF and GOF Member 1 of the Shab family of potassium channels (Kv2.1) Voltage Potassium KCNB1 (Torkamani et al. 2014) 
 EOEE Dominant Unknown Member 5 of the Ether-a-go-go family of potassium channels 
(Kv10.2) 







Voltage-gated potassium channel, Q subfamily, member 2 
(Kv7.2) 
Voltage Potassium KCNQ2 (Weckhuysen et al. 2012) 
(Millichap et al. 2017) 
(H) EIMFS Dominant GOF Calcium-activated potassium channel (subfamily T) member 1 
(Kca4.1) 
Calcium  Potassium KCNT1 (Barcia et al. 2012) 
CALCIUM CHANNELS 
        
(I) EOEE Dominant LOF α1A subunit of the P/Q type voltage-gated calcium channel 
(Cav2.1) 
Voltage Calcium CACNA1A (Damaj et al. 2015) 
 Epileptic encephalopathy Recessive LOF α2δ2 auxiliary subunit of the P/Q voltage-gated calcium 
channel 
Voltage Calcium CACNA2D2 (Pippucci et al. 2013) 
GLUTAMATE RECEPTORS 
 Epileptic-dyskinetic encephalopathy Recessive LOF Accessory protein to the neuronal AMPA receptor Glutamate Cations FRRS1L (Madeo et al. 2016) 
 EOEE Dominant LOF Subunit 1 of the neuronal NMDA receptor Glutamate Cations GRIN1 (Ohba et al. 2015) 
 Focal epilepsy + speech difficulties Dominant LOF and GOF Subunit 2A of the neuronal NMDA receptor Glutamate Cations GRIN2A (Carvill et al. 2013) 
 Focal epilepsy + speech difficulties Dominant  LOF and GOF Subunit 2B of the neuronal NMDA receptor Glutamate Cations GRIN2B (Lemke et al. 2014) 














(J) EOEE Dominant LOF α1 subunit of the neuronal GABA-A receptor GABA Chloride GABRA1 (Kodera et al. 2016) 
 Epileptic encephalopathy Dominant LOF β1 subunit of the neuronal GABA-A receptor GABA Chloride GABRB1 (Janve et al. 2016) 
(K) EOEE Dominant LOF LOF β3 subunit of the neuronal GABA-A receptor GABA Chloride GABRB3 (Janve et al. 2016) 
(L) EOEE Dominant LOF γ2 subunit of the neuronal GABA-A receptor GABA Chloride GABRG2 (Shen et al. 2016) 
OTHER CHANNELS 
(M) EOEE Dominant  LOF α3 isoform of sodium/potassium ATPase ATP Sodium/Potassi
um 
ATP1A3 (Paciorkowski et al. 2015) 
 EOEE Dominant LOF and GOF  
Hyperpolarization-activated, cyclic nucleotide–gated (HCN) 
channel, type 1 
Hyperpolarisation Cations HCN1 (Nava et al. 2014) 
 EIMFS Recessive LOF LOF Potassium and chloride transporter (KCC2) Potassium Potassium and 
chloride 
SLC12A5 (Stodberg et al. 2015) 
SELF-LIMITING FAMILIAL EPILEPSIES WITH ONSET IN THE NEONATAL OR EARLY INFANTILE PERIOD 
(G) Self-limiting familial neonatal seizures Dominant  LOF Voltage-gated potassium channel, Q subfamily, member 2 
(Kv7.2) 
Voltage Potassium KCNQ2 (Biervert et al. 1998) 
(N) Self-limiting familial neonatal seizures Dominant LOF and GOF Voltage-gated potassium channel, Q subfamily, member 3 
(Kv7.3) 
Voltage Potassium  KCNQ3 (Charlier et al. 1998) 
(A) GEFS+ Dominant LOF α subunit of the type 1 neuronal voltage-gated sodium 
channel (Nav1.1) 
Voltage Sodium SCN1A (Claes et al. 2001) 




LOF β1 auxiliary subunit for the type 1 neuronal voltage-gated 
sodium channel 
Voltage Sodium SCN1B (Wallace et al. 1998) 
(C) Self-limiting familial neonatal-infantile 
seizures 
Dominant LOF α subunit of the type 2 neuronal voltage-gated sodium 
channel (Nav1.2) 
Voltage Sodium SCN2A (Berkovic et al. 2004) 
(D) Infantile convulsions choreoathetosis 
(ICCA) syndrome 
Dominant LOF α subunit of the type 6 neuronal voltage-gated sodium 
channel (Nav1.6) 
Voltage Sodium SCN8A (Gardella et al. 2015) 
(O) GEFS+ Dominant Unknown α subunit of the type 7 neuronal voltage-gated sodium 
channel (Nav1.7) 
Voltage Sodium SCN9A (Mulley et al. 2013) 
AUTOSOMAL DOMINANT NOCTURNAL FRONTAL LOBE EPILEPSY 
 Nocturnal frontal lobe epilepsy Dominant GOF α2 subunit of the nicotinic acetylocholine receptor Acetylcholine Cations  CHRNA2 (Combi, Ferini-Strambi & 
Tenchini 2009) 
 Nocturnal frontal lobe epilepsy Dominant GOF α4 subunit of the nicotinic acetylocholine receptor Acetylcholine Cations  CHRNA4 (Steinlein et al. 1995) 
 Nocturnal frontal lobe epilepsy Dominant GOF α4 subunit of the nicotinic acetylocholine receptor Acetylcholine Cations  CHRNB2 (Phillips et al. 2001) 
(H) Nocturnal frontal lobe epilepsy Dominant GOF Calcium-activated potassium channel (subfamily T) member 1 
(Kca4.1) 
Calcium  Potassium KCNT1 (Heron et al. 2012) 
SUSCEPTIBILITY TO IDIOPATHIC GENERALISED EPILEPSIES 
(P) Susceptibility to IGE Dominant GOF α1H subunit of the T type calcium channel (Cav3.2) Voltage Calcium CACNA1H (Heron et al. 2007) 
(Q) Susceptibility to JME Dominant Unknown β4 auxiliary subunit of the P/Q voltage-gated calcium channel Voltage Calcium CACNB4 (Escayg et al. 2000) 
 Susceptibility to IGE Dominant LOF (microdeletions 
only) 
α7 subunit of the nicotinic acetylocholine receptor Acetylcholine Cations  CHRNA7 (Dibbens et al. 2009) 













(J) Susceptibility to IGE Dominant  LOF α1 subunit of the neuronal GABA-A receptor GABA Chloride GABRA1 (Lachance-Touchette et 
al. 2011) 
(K) Susceptibility to IGE Dominant LOF β3 subunit of the neuronal GABA-A receptor GABA Chloride GABRB3 (Tanaka et al. 2008) 
 Susceptibility to IGE Dominant  LOF δ subunit of the neuronal GABA-A receptor GABA Chloride GABRD (Dibbens et al. 2004) 
(L) Susceptibility to IGE 





γ2 subunit of the neuronal GABA-A receptor GABA Chloride GABRG2 (Lachance-Touchette et 
al. 2011) 
(Boillot et al. 2015) 
OTHER EPILEPSIES 
 Variable epilepsy phenotype – ranging 
from epileptic encephalopathy to well-
controlled seizures 
X-linked recessive LOF Type 4 voltage-gated chloride channel Voltage Chloride CLCN4 (Palmer et al. 2016) 
 Progressive myoclonic epilepsy Dominant 
 
LOF Member 1 of the Shaw family of potassium channels (Kv3.1) Voltage Potassium KCNC1 (Muona et al. 2015) 
 Epilepsy and paroxysmal movement 
disorder 
Dominant  GOF α subunit of the large conductance calcium-sensitive 
potassium channel (BK) 
Calcium Potassium  KCNMA1 (Du et al. 2005) 
(N) Familial focal epilepsy Dominant  LOF Voltage-gated potassium channel, Q subfamily, member 3 
(Kv7.3) 
Voltage Potassium  KCNQ3 (Miceli et al. 2015) 
 Childhood-onset focal epilepsy Dominant LOF and GOF α subunit of the type 3 neuronal voltage-gated sodium 
channel (Nav1.3) 
Voltage Sodium SCN3A (Vanoye et al. 2014) 
OTHER NEUROLOGICAL DISORDERS 
MOVEMENT DISORDERS AND RELATED PHENOTYPES 
 Familial hemiplegic migraine 
Familial basilar migraine 







α2 isoform of sodium/potassium ATPase ATP Sodium/ 
Potassium 
ATP1A2 (Fusco et al. 2003) 
(Ambrosini et al. 2005) 
(Swoboda et al. 2004) 
(M) Alternating hemiplegia of childhood  








α3 isoform of sodium/potassium ATPase ATP Sodium/ 
Potassium 
ATP1A3 (Rosewich H. et al. 2012) 
(de Carvalho et al. 2004) 
(Demos et al. 2014) 
(I) Familial hemiplegic migraine 
Episodic ataxia type 2 
Progressive spinocerebellar ataxia 







α1A subunit of the P/Q type voltage-gated calcium channel 
(Cav2.1) 
Voltage Calcium CACNA1A (Ophoff et al. 1996) 
(Ophoff et al. 1996) 
(Matsuyama et al. 1997) 






α1S subunit of the L type voltage-gated calcium channel 
(Cav1.1) 
Voltage Calcium CACNA1S (Ptáček et al. 1991) 
(Q) Episodic ataxia type 5 
 
Dominant Unknown β4 auxiliary subunit of the P/Q voltage-gated calcium channel Voltage Calcium CACNB4 (Escayg A et al. 2000) 
(R) Leukoencephalopathy with ataxia Recessive LOF Type 2 voltage-gated chloride channel Voltage Chloride CLCN2 (Depienne et al. 2013) 
 Hyperekplexia Dominant or 
recessive 
GOF α1 subunit of the spinal glycine receptor Glycine Chloride GLRA1 (Thomas et al. 2013) 
 Hyperekplexia Dominant or 
recessive  













 Episodic ataxia type 1 Dominant  LOF α1 subunit of the Shaker family potassium channels (Kv1.1) Voltage Potassium KCNA1 (Zuberi et al. 1999) 
(F) Hereditary spastic paraplegia and ataxia Dominant  LOF α2 subunit of the Shaker family potassium channels (Kv1.2) Voltage Potassium KCNA2 (Helbig et al. 2016) 
 Spinocerebellar ataxia Dominant  LOF Member 3 of the Shaw family of potassium channels (Kv3.3) Voltage Potassium KCNC3 (Waters et al. 2006) 
(S) Early-onset cerebellar ataxia, 







Member 3 of the Shal family of potassium channels (Kv4.3) Voltage Potassium KCND3 (Smets et al. 2015) 
(Duarri et al. 2012) 
(A) Familial hemiplegic migraine Dominant GOF GOF α subunit of the type 1 neuronal voltage-gated sodium 
channel (Nav1.1) 
Voltage Sodium SCN1A (Dichgans et al. 2005) 
NEUROMUSCULAR DISORDERS 
 Slow channel congenital myasthenic 
syndrome 
Fast channel congenital myasthenic 
syndrome 







α1 subunit of the nicotinic acetylcholine receptor Acetylcholine Cations  CHRNA1 (Engel et al. 1996) 
(Wang et al. 1999) 
(Michalk et al. 2009) 
 Slow channel congenital myasthenic 
syndrome 
Congenital myasthenic syndrome 






β1 subunit of the nicotinic acetylcholine receptor Acetylcholine Cations  CHRNB1 (Engel et al. 1996) 
(Quiram et al. 1999) 
 Slow channel congenital myaesthenic 
syndrome 
Fast channel congenital myasthenic 
syndrome 
Congenital myasthenic syndrome 
associated with Ach receptor deficiency  










δ polypeptide subunit of the nicotinic acetylcholine receptor Acetylcholine Cations CHRND (Gomez et al. 2002) 
(Gomez et al. 2002) 
(Müller et al. 2006) 
(Michalk et al. 2009) 
 Slow channel congenital myasthenic 
syndrome 
Fast channel congenital myasthenic 
syndrome 
Congenital myasthenic syndrome 









ε polypeptide subunit of the nicotinic acetylcholine receptor Acetylcholine Cations CHRNE (Ohno et al. 1995) 
(Ohno et al. 1996) 
(Ohno et al. 1997) 
 Multiple pterygium syndrome (lethal 
and Escobar variants) 
Recessive  LOF γ subunit of the nicotinic acetylcholine receptor Acetylcholine Cations CHRNG (Hoffmann et al. 2006) 
(Morgan et al. 2006) 
 
 Dominant myotonia congenita 





Skeletal muscle voltage-gated chloride channel Voltage Chloride CLCN1 (Koch et al. 1992) 
(Lorenz et al. 1994) 
 Dominant central core disease 
Recessive central core disease 
Malignant hyperthermia 







Skeletal muscle Ryanodine receptor 1 Calcium Calcium RYR1 (Zhang et al. 1993) 
(Jungbluth et al. 2002, 
Monnier et al. 2005) 















Recessive  LOF 
 Hyperkalaemic periodic paralysis 
Hypokalaemic periodic paralysis 
Paramyotonia congenita  









α subunit of the type 4 neuronal voltage-gated sodium 
channel (Nav1.4) 
Voltage Sodium SCN4A (Ptáček et al. 1994) 
(Jurkat-Rott et al. 2000) 
(Ptáček et al. 1992) 
(Tsujino et al. 2003) 
PERIPHERAL NERVE DISORDERS 
(R) Peripheral nerve hyperexitability Dominant  LOF Voltage-gated potassium channel, Q subfamily, member 2 
(Kv7.2) 
Voltage Potassium KCNQ2 (Wuttke et al. 2007) 
(O) Erytheromelalgia and related 
neuropathic pain syndromes 





α subunit of the type 7 neuronal voltage-gated sodium 
channel (Nav1.7) 
Voltage Sodium SCN9A (Fischer, Waxman 2010) 
(Cox et al. 2006) 
(E) Episodic pain syndrome Dominant GOF α subunit of the type 8 neuronal voltage-gated sodium 
channel (Nav1.8) 
Voltage Sodium SCN10A (Faber et al. 2012) 
 Familial episodic pain syndrome 






α subunit of the type 9 neuronal voltage-gated sodium 
channel (Nav1.9) 
Voltage Sodium SCN11A (Zhang et al. 2013) 
(Leipold et al. 2013) 
 Familial episodic pain syndrome Dominant  GOF Transient receptor potential cation channel, family A, 
member 1 
Various ligands, 
activated by noxious 
stimuli 
Cations TRPA1 (Kremeyer et al. 2010) 
DEAFNESS 
 Hearing loss Dominant  LOF Voltage-gated potassium channel, Q subfamily, member 4 
(Kv7.4) 
Voltage Potassium KCNQ4 (Coucke et al. 1999) 
CARDIAC DISEASE 
SODIUM CHANNELS 
(B) Familial atrial fibrillation 
Brugada syndrome 







β auxiliary subunit for the type 1 neuronal voltage-gated 
sodium channel 
Voltage Sodium SCN1B (Watanabe et al. 2008) 
 Familial atrial fibrillation Dominant  LOF β auxiliary subunit for the type 2 neuronal voltage-gated 
sodium channel 
Voltage Sodium SCN2B (Watanabe et al. 2009) 






β auxiliary subunit for the type 3 neuronal voltage-gated 
sodium channel 
Voltage Sodium SCN3B (Wang et al. 2010) 
(Hu et al. 2009) 
 Familial atrial fibrillation 





β auxiliary subunit for the type 4 neuronal voltage-gated 
sodium channel 
Voltage Sodium SCN4B (Olesen et al. 2011) 
(Medeiros-Domingo et al. 
2007) 












α subunit of the type 5 neuronal voltage-gated sodium 
channel (Nav1.5) 
Voltage Sodium SCN5A (Ellinor et al. 2008, Chen 
et al. 1998) 
(McNair et al. 2004) 
(Schott et al. 1999) 
(Bennett et al. 1995) 













Long QT syndrome 
Polymorphic ventricular tachycardia 







(Swan et al. 2014) 
(Benson et al. 2003) 
POTASSIUM CHANNELS 
(T) Ventricular tachycardia and dilated 
cardiomyopathy 
Dominant LOF ATP-sensitive potassium channel (KATP) ATP Potassium ABCC9 (Bienengraeber et al. 
2004) 
 Familial atrial fibrillation Dominant  LOF α5 subunit of the Shaker family potassium channels (Kv1.5) Voltage Potassium KCNA5 (Olson et al. 2006) 






Member 3 of the Shal family of potassium channels (Kv4.3) Voltage Potassium KCND3 (Giudicessi et al. 2012) 
(Olesen et al. 2013) 
 Long QT syndrome 





Member 2 of the Ether-a-go-go (EAG) type potassium 
channels (Kv10.2) 
Voltage Potassium KCNH2 (Curran et al. 1995) 
(Brugada et al. 2004) 
 Jervell and Lange-Nielsen syndrome 





Member 1 of the MinK subfamily of potassium channels Voltage Potassium KCNE1 (Tyson et al. 1997) 
(Splawski et al. 1997) 
 Familial atrial fibrillation 





Member 1 of the MinK related peptide subfamily of 
potassium channels (MiRP1) (membrane subunit which 
assembles with Kv10.2) 
Voltage  Potassium KCNE2 (Yang et al. 2004) 
(Abbott et al. 1999) 
 Brugada syndrome Dominant  LOF Member 2 of the MinK related peptide subfamily of 
potassium channels (MiRP1) (membrane subunit which 
assembles with Kv10.2) 
Voltage  Potassium KCNE3 (Van Norstrand et al. 
2007) 
 Familial atrial fibrillation 
Jervell and Lange-Neilsen syndrome 
Long QT syndrome 









Voltage-gated potassium channel, Q subfamily, member 1 
(Kv7.1) 
Voltage Potassium KCNQ1 (Chen et al. 2003) 
(Neyroud et al. 1997) 
(Wang et al. 1996) 




Familial atrial fibrillation 







Member 2 of the J family of inwardly rectifying voltage-gated 
potassium channels (Kir2.1) 
Voltage Potassium KCNJ2 (Plaster et al. 2001) 
(Xia et al. 2005) 
(Priori et al. 2005) 
(V) Long QT syndrome Dominant  LOF G-protein-activated inwardly rectifying voltage-gated 
potassium channel (Kir3.4) 
G-protein activation Potassium  KCNJ5 (Yang et al. 2010) 
CALCIUM CHANNELS 






α1C subunit of the L type voltage-gated calcium channel 
(Cav1.2) 
Voltage Calcium CACNA1C (Antzelevitch et al. 2007) 
(Splawski et al. 2004) 
 Brugada syndrome Dominant  LOF β2 subunit of the L type voltage-gated calcium channel Voltage Calcium CACNB2 (Antzelevitch et al. 2007) 
 Brugada syndrome Dominant  LOF α1δ subunit of the L type voltage-gated calcium channel  Voltage Calcium CACNA2D1 (Antzelevitch et al. 2007) 








Cardiac ryanodine receptor 2 Calcium Calcium RYR2 (Tiso et al. 2001) 
(Priori et al. 2001) 
CATION CHANNELS 













Sick sinus syndrome Dominant LOF channel, type 4 (Milanesi et al. 2006) 
RENAL DISEASE 




LOF β subunit of the renal chloride channel  Chloride BSND (Birkenhager et al. 2001) 




X-linked recessive  LOF Type 5 voltage-gated chloride channel Voltage Chloride CLCN5 (Lloyd et al. 1996) 
 
 Barrter’s syndrome with sensorineural 
deafness 
Digenic recessive  LOF Renal chloride channel  Chloride CLCNKA 
and 
CLCNKB 
(Schlingmann et al. 2004) 
 Barrter’s syndrome Recessive  LOF Renal outer-medullar potassium channel (Kir1.1) Voltage Potassium KCNJ1 (Simon et al. 1996b) 
(W) Liddle syndrome Dominant  GOF β subunit of the epithelial sodium channel Voltage Sodium SCNN1B (Shimkets et al. 1994) 
 Barrter’s syndrome Recessive  LOF Type 1 renal sodium/potassium/chloride transporter (NKCC2)  Sodium, 
potassium and 
chloride 
SLC12A1 (Simon et al. 1996a) 
 Gitelman syndrome Recessive  LOF Type 3 renal sodium/potassium/chloride transporter (NKCC2)  Sodium, 
potassium and 
chloride 
SLC12A3 (Simon et al. 1996c) 
ENDOCRINE AND BONE DISEASE 
 Permanent neonatal diabetes mellitus 
+/- neurologic features 
Transient neonatal diabetes mellitus 
Persistent hyperinsulinaemic 








ATP-binding cassette of the sulphonylurea receptor Sulphonylurea and 
ATP 
Potassium ABCC8 (Proks et al. 2006) 
(Babenko et al. 2006) 
(Thomas et al. 1995) 
 
(T) Cantú syndrome (hypertrichotic 
osteochondrodysplasia) 
Dominant GOF ATP-sensitive potassium channel (KATP) ATP Potassium ABCC9 (van Bon et al. 2004)  
(P) Familial hyperaldosteronism Dominant GOF α1H subunit of the T type calcium channel (Cav3.2) Voltage Calcium CACNA1H (Scholl et al. 2015) 






Type 7 chloride channel  Chloride CLCN7 (Cleiren et al. 2001) 
(Kornak et al. 2001) 
(V) Familial hyperaldosteronism Dominant LOF G-protein-activated inwardly rectifying voltage-gated 
potassium channel (Kir3.4) 
G-protein activation Potassium  KCNJ5 (Choi et al. 2011) 
 Permanent neonatal diabetes, with 
neurological features (Delay, Epilepsy, 
Neonatal Diabetes, DEND syndrome) 
Persistent hyoerinsulinaemic 
hypoglycaemia of infancy 
Transient neonatal diabetes 
Permanent neonatal diabetes 
Dominant GOF Member 11 of the inward rectifier type of potassium 
channels (Kir6.2) 













Maturity-onset diabetes if the young 
(MODY) 
(W) Pseudohypoaldosteronism Recessive  LOF β subunit of the epithelial sodium channel Voltage Sodium SCNN1B (Chang et al. 1996) 
(O) Osteogenesis imperfecta Recessive Unknown α subunit of the type 7 neuronal voltage-gated sodium 
channel (Nav1.7) 
Voltage Sodium SCN9A (Caparros-Martin et al. 
2016) 
MISCELLANEOUS/MULTISYSTEM DISEASES 
 Primary aldosteronism, seizures, and 
neurologic abnormalities Sinoatrial 





α1D subunit of the L type calcium channel (Cav1.3) Voltage Calcium CACNA1D (Scholl et al. 2013) 
(Baig et al. 2011) 
 Cystic fibrosis Recessive LOF Cystic fibrosis transmembrane conductance regulator ATP Chloride CFTR (Kerem et al. 1989) 






Member 1 of the Ether-a-go-go (EAG) type potassium 
channels (Kv10.1) 
Voltage Potassium KCNH1 (Simons et al. 2015) 
(Kortum et al. 2015) 
(U) 
 
Andersen-Tawil syndrome Dominant  
 
LOF Member 2 of the J family of inwardly rectifying voltage-gated 
potassium channels (Kir2.1) 
Voltage Potassium KCNJ2 (Plaster et al.) 
(V) Andersen-Tawil syndrome (without 
dysmorphism) 
Dominant  LOF G-protein-activated inwardly rectifying voltage-gated 
potassium channel (Kir3.4) 
G-protein activation Potassium  KCNJ5 (Kokunai et al. 2014) 
 SESAME (seizures, sensorineural 
deafness, ataxia, intellectual disability) 
or EAST (epilepsy, ataxia, sensorineural 
deafness and tubulopathy) syndrome 
Recessive  LOF Member 10 of the inward rectifier type of potassium 
channels (Kir4.1) 
Voltage Potassium  KCNJ10 (Bockenhauer D et al. 
2009) 
 Familial pulmonary arterial 
hypertension 
Dominant  LOF Member 1 of the Task family of two pore potassium channels Voltage Potassium  KCNK3 (Ma et al. 2013) 
(W) Bronchiectasis Dominant  LOF β subunit of the epithelial sodium channel Voltage Sodium SCNN1B (Sheridan et al. 2005) 
 Nonepidermolytic focal palmoplantar 
ketatoderma (Olmsted syndrome) 
Dominant  GOF Transient receptor potential cation channel, subfamily V, 
member 3 




Hereditary sensorimotor neuropathy 
Metatropic dysplasia 
Parastremmatic dwarfism 
Scapuloperitoneal muscular atrophy 
Spondyloepiphyseal dysplasia 

















Transient receptor potential cation channel, subfamily V, 




Calcium TRPV4 (Rock et al. 2008) 
(Lamande et al. 2011) 
(Auer-Grumbach et al. 
2010) 
(Krakow et al. 2009) 
(Nishimura et al. 2010) 
(Auer-Grumbach et al. 
2010) 
(Krakow et al. 2009) 
(Auer-Grumbach et al. 
2010) 
Table 1 – the known human channelopathies. Abbreviations used: EOEE – early-onset developmental and epileptic encephalopathy; EIMFS – epilepsy of 
infancy with migrating focal seizures; IGE: Idiopathic generalised epilepsy; JME – juvenile myoclonic epilepsy; CAPOS syndrome - Cerebellar ataxia, Areflexia, 














Ion channels can be classified by the mechanism by which they are activated, and/or by the ion(s) that they are 
permeable to. In the former system, there are three groups of ion channel: 1. Voltage-gated channels; 2. Extracellular 
ligand-gated channels; and 3. Intracellular ligand-gated channels.
Voltage-gated channels Extracellular Ligand-gated channels Intracellular Ligand-gated channels
• Ion permeability varies in 
association with changes in 
electrical membrane potential near 
the channel.
• Important in tissues where rapid 
conduction of messages is required, 
such as in nerves, cardiac 
conduction cells, and skeletal 
muscle.
• The sequence encoding the 
voltage-sensing region is highly 
conserved across evolution, and is 
intolerant of genetic variation.
• Voltage-gated ion channels are 
typically  composed of tetramers of 
4 pore-forming subunits (see Fig. 
1).
• Sodium, potassium, and calcium 
channels are the most prevalent
• There are 9 subtypes of sodium 
channel, 16 subtypes of calcium 
channel, and >50 subtypes of 
potassium channel.  Each subtype is 
encoded by a different gene (e.g. 
SCN1A, SCN2A, SCN3A etc.).
• Highly cell-specific expression of 
ion channel subtypes is critical for 
physiological function. As an 
example, Nav1.5 channels, encoded 
by SCN5A are expressed in the 
heart, whereas Nav1.1 (SCN1A), 
Nav1.2(SCN2A), Nav1.3(SCN3A), and 
Nav1.6(SCN8A) are expressed in the 
central nervous system (Grubman
et al. 1988).
Fig 1. Schematic of the voltage-gated sodium channel: A: momomer; B:





D1 D2 D3 D4
A
• In the brain Nav1.1 subunits localise to inhibitory neurons(Ogiwara et al. 2007) whilst Nav1.2 and Nav1.6 localise to 
excitatory neurones (Gordon et al. 1987, Chen et al. 2008). 
• Time-dependent expression of ion channels is likely to be critical for normal development, and is thought to be 
responsible for the age-specific presentation of many channelopathies. In the rodent central nervous system, 
during embryonic life Nav1.3 subunits are most highly expressed sodium channels in the brain, whereas Nav1.1 
and Nav1.2 take over from birth. Nav1.1 expression gradually increases through young adulthood (Gordon et al. 
1987, Beckh et al. 1989). 
• Activated by ligand-binding, and 
may be permeable to chloride 
(as in GABA receptors) or anions 
(as in glutamatergic receptors 
and acetylcholine receptors).
• Open in response to changes in 
concentration of intracellular 
substrates, such as ATP (for 
example pancreatic ATP-
sensitive potassium channels).
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